지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 7 - 18 (12page)
이용수
초록· 키워드
오류제보하기
AbstractMultiple myeloma (MM) is the third most common hematologic malignancy in Korea. Historically, the incidence of MM in Korea has been lower than that in Western populations,although there is growing evidence that the incidence of MM in Asian populations,including Korea, is increasing rapidly. Despite advances in the management ofMM, patients will ultimately relapse or become refractory to their current treatment, andalternative therapeutic options are required in the relapsed/refractory setting. In Korea,although lenalidomide/dexamethasone is indicated for the treatment of relapsed or refractoryMM (RRMM) in patients who have received at least one prior therapy, lenalidomideis reimbursable specifically only in patients with RRMM who have failed bortezomib-based treatment. Based on evidence from pivotal multinational clinical trials as wellas recent studies in Asia, including Korea, lenalidomide/dexamethasone is an effectivetreatment option for patients with RRMM, regardless of age or disease status. Adverseevents associated with lenalidomide/dexamethasone, including hematologic toxicity, venousthromboembolism, fatigue, rash, infection, and muscle cramps, are largely predictableand preventable/manageable with appropriate patient monitoring and/or the use ofstandard supportive medication and dose adjustment/interruption. Lenalidomide/dexamethasoneprovides an optimal response when used at first relapse, and treatmentshould be continued long term until disease progression. With appropriate modificationof the lenalidomide starting dose, lenalidomide/dexamethasone is effective in patientswith renal impairment and/or cytopenia. This review presents updated evidence from thepublished clinical literature and provides recommendations from an expert panel ofKorean physicians regarding the use of lenalidomide/dexamethasone in patients withRRMM.
목차
등록된 정보가 없습니다.
참고문헌 (74)
참고문헌 신청
Raab MS / 2009 / Multiple myeloma / Lancet 374:324~339
Hyeon Jin Park / 2012 / Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008 / Blood Research 47(1):28~38
Vallet S / 2013 / New insights, recent advances, and current challenges in the biological treatment of multiple myeloma / Expert Opin Biol Ther 13(Suppl 1):S35~S53
Lee JH / 2010 / Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party / Int J Hematol 92:52~57
Kim K / 2014 / Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study / Am J Hematol 89:751~756
Hyeon Jin Park / 2012 / Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008 / Blood Research 47(1):28~38
Vallet S / 2013 / New insights, recent advances, and current challenges in the biological treatment of multiple myeloma / Expert Opin Biol Ther 13(Suppl 1):S35~S53
Lee JH / 2010 / Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party / Int J Hematol 92:52~57
Kim K / 2014 / Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study / Am J Hematol 89:751~756
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Lenalidomide in Treating Patients with Castration-Resistant Prostate Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
골수형성이상증후군 환자의 레날리도마이드 치료
대한내과학회지
2020 .04
-
Pooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
21세기 다발골수종의 단일 기관 현실 세계 경험
대한내과학회지
2022 .04
-
다발골수종의 새로운 치료 약제들
대한내과학회지
2015 .01
-
An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
Gut and Liver
2018 .01
-
Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
Blood Research
2022 .03
-
Salvage treatment of relapsed/refractory LCH
Blood Research
2016 .01
-
Treatment Outcomes in Children and Adolescents with Relapsed or Progressed Solid Tumors: a 20-year, Single-Center Study
Journal of Korean Medical Science
2018 .01
-
다발골수종 치료의 최신지견
대한의사협회지
2023 .04
-
Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
Cancer Research and Treatment
2023 .04
-
Heavy-chain deposition disease associated with multiple myeloma: a case report
고신대학교 의과대학 학술지
2024 .09
-
Predictors of Relapse in Patients with Organizing Pneumonia
Tuberculosis and Respiratory Diseases
2015 .01
-
Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma
전남의대학술지
2019 .01
-
불응성/재발성 다발골수종의 볼테조밉 구제 치료의 실제: 단일 기관의 경험
대한내과학회지
2015 .01
-
The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non‒Small Cell Lung Cancer
Cancer Research and Treatment
2022 .10
-
The effect of combination treatment using palonosetron and dexamethasone for the prevention of postoperative nausea and vomiting versus dexamethasone alone in women receiving intravenous patient-controlled analgesia
Korean Journal of Anesthesiology
2015 .01
-
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn’s disease patients: Taiwan Society of Inflammatory Bowel Disease Study
Intestinal research
2017 .01
-
Review of dexamethasone administration for management of complications in postoperative third molar surgery
대한구강악안면외과학회지
2021 .10
-
Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in Intestinal Behçet’s Disease
Gut and Liver
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0